Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

ROCKET AF Investigators; Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf

doi:10.1056/NEJMoa1009638

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

ROCKET AF Investigators, Manesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, Guohua Pan, Daniel E Singer, Werner Hacke, Günter Breithardt, Jonathan L Halperin, Graeme J Hankey, Jonathan P Piccini, Richard C Becker, Christopher C Nessel, John F Paolini, Scott D Berkowitz, Keith A A Fox, Robert M Califf

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin.

Original language	English
Pages (from-to)	883-891
Number of pages	9
Journal	New England Journal of Medicine
Volume	365
Issue number	10
DOIs	https://doi.org/10.1056/NEJMoa1009638
Publication status	Published - 2011

Access to Document

10.1056/NEJMoa1009638

Cite this

ROCKET AF Investigators, Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., Becker, R. C., Nessel, C. C., Paolini, J. F., Berkowitz, S. D., Fox, K. A. A., & Califf, R. M. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine, 365(10), 883-891. https://doi.org/10.1056/NEJMoa1009638

@article{51512332269f4bb1b1623977bd23f7f5,

title = "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation",

abstract = "The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin.",

author = "{ROCKET AF Investigators} and Patel, {Manesh R} and Mahaffey, {Kenneth W} and Jyotsna Garg and Guohua Pan and Singer, {Daniel E} and Werner Hacke and G{\"u}nter Breithardt and Halperin, {Jonathan L} and Hankey, {Graeme J} and Piccini, {Jonathan P} and Becker, {Richard C} and Nessel, {Christopher C} and Paolini, {John F} and Berkowitz, {Scott D} and Fox, {Keith A A} and Califf, {Robert M}",

year = "2011",

doi = "10.1056/NEJMoa1009638",

language = "English",

volume = "365",

pages = "883--891",

journal = "New England Journal of Medicine",

issn = "1533-4406",

publisher = "MASSACHUSETTS MEDICAL SOC",

number = "10",

}

ROCKET AF Investigators, Patel, MR, Mahaffey, KW, Garg, J, Pan, G, Singer, DE, Hacke, W, Breithardt, G, Halperin, JL, Hankey, GJ, Piccini, JP, Becker, RC, Nessel, CC, Paolini, JF, Berkowitz, SD, Fox, KAA & Califf, RM 2011, 'Rivaroxaban versus warfarin in nonvalvular atrial fibrillation', New England Journal of Medicine, vol. 365, no. 10, pp. 883-891. https://doi.org/10.1056/NEJMoa1009638

TY - JOUR

T1 - Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

AU - ROCKET AF Investigators

AU - Patel, Manesh R

AU - Mahaffey, Kenneth W

AU - Garg, Jyotsna

AU - Pan, Guohua

AU - Singer, Daniel E

AU - Hacke, Werner

AU - Breithardt, Günter

AU - Halperin, Jonathan L

AU - Hankey, Graeme J

AU - Piccini, Jonathan P

AU - Becker, Richard C

AU - Nessel, Christopher C

AU - Paolini, John F

AU - Berkowitz, Scott D

AU - Fox, Keith A A

AU - Califf, Robert M

PY - 2011

Y1 - 2011

N2 - The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin.

AB - The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin.

UR - http://www.scopus.com/inward/record.url?scp=80052592404&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1009638

DO - 10.1056/NEJMoa1009638

M3 - Article

C2 - 21830957

SN - 1533-4406

VL - 365

SP - 883

EP - 891

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 10

ER -

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Abstract / Description of output

Access to Document

Other files and links

Fingerprint

Cite this